Abstract

BackgroundPeripheral blood biomarkers might improve diagnostic accuracy for idiopathic pulmonary fibrosis (IPF).ResultsGene expression profiles were obtained from 89 patients with IPF and 26 normal controls. Samples were stratified according to severity of disease based on pulmonary function. The stratified dataset was split into subsets; two-thirds of the samples were selected to comprise the training set, while one-third was reserved for the validation set. Bayesian probit regression was used on the training set to develop a gene expression model for IPF versus normal. The gene expression model was tested by using it on the validation set to perform class prediction. Unsupervised clustering failed to discriminate between samples of different severity. Therefore, samples of all severities were included in the training and validation sets, in equal proportions. A gene signature model was developed from the training set. The model was built in an iterative fashion with the number of gene features selected to minimize the misclassification error in cross validation. The final model was based on the top 108 discriminating genes in the training set. The signature was successfully applied to the validation set, ROC area under the curve = 0.893, p < 0.0001. Using the optimal threshold (0.74) accurate class predictions were made for 77% of the test cases with sensitivity = 0.70, specificity = 1.00.ConclusionsBy using Bayesian probit regression to develop a model, we show that it is entirely possible to make a diagnosis of IPF from the peripheral blood with gene signatures.Electronic supplementary materialThe online version of this article (doi:10.1186/1471-2164-15-902) contains supplementary material, which is available to authorized users.

Highlights

  • Peripheral blood biomarkers might improve diagnostic accuracy for idiopathic pulmonary fibrosis (IPF)

  • Only 115 samples were included in this analysis; these 115 samples are a subset of the complete dataset that is available through the Gene Expression Omnibus

  • Study subjects Of the 115 samples in this cohort, 48 were obtained from subjects with sporadic IPF; 41 samples were obtained from cases of familial IPF; and 26 samples were obtained from non-diseased healthy controls (Table 1)

Read more

Summary

Introduction

Peripheral blood biomarkers might improve diagnostic accuracy for idiopathic pulmonary fibrosis (IPF). While IPF is a significant cause of morbidity and mortality worldwide, the standard approach to diagnosing IPF can be quite challenging [1,2,3]. It requires integration of clinical, pathological and radiological data. The diagnosis of IPF must carry a modifier: definitive, probable or merely possible [1]. Given these conditions, at least 10% of all cases of interstitial lung disease (ILD) remain unclassified [6,7,8,9]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call